In the initial proof-of-principle experiments, we showed that specific silencing of IDH2 could profoundly inhibit TNBC cell proliferation and induced apoptosis in culture (Fig. 1e–i), and could effectively suppress tumor growth in vivo (Fig. 1l). Here, IDH2 is linked to neoplasm.